Evidence-based initiation of dopaminergic therapy in Parkinson's disease.
Identifieur interne : 001A50 ( Main/Exploration ); précédent : 001A49; suivant : 001A51Evidence-based initiation of dopaminergic therapy in Parkinson's disease.
Auteurs : Janis M. Miyasaki [Canada]Source :
- Journal of neurology [ 1432-1459 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Dopamine Agents.
- chemical , adverse effects : Dopamine Agents.
- diagnosis : Parkinson Disease.
- drug therapy : Parkinson Disease.
- prevention & control : Dyskinesia, Drug-Induced.
- standards : Evidence-Based Medicine.
- Humans.
Abstract
The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.
DOI: 10.1007/s00415-010-5718-x
PubMed: 21080195
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C90
- to stream PubMed, to step Curation: 000C90
- to stream PubMed, to step Checkpoint: 000C90
- to stream Ncbi, to step Merge: 000D77
- to stream Ncbi, to step Curation: 000D77
- to stream Ncbi, to step Checkpoint: 000D77
- to stream Main, to step Merge: 001B58
- to stream Main, to step Curation: 001A50
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evidence-based initiation of dopaminergic therapy in Parkinson's disease.</title><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M" last="Miyasaki">Janis M. Miyasaki</name><affiliation wicri:level="1"><nlm:affiliation>The Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, ON, Canada. miyasaki@uhnresearch.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:21080195</idno><idno type="pmid">21080195</idno><idno type="doi">10.1007/s00415-010-5718-x</idno><idno type="wicri:Area/PubMed/Corpus">000C90</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C90</idno><idno type="wicri:Area/PubMed/Curation">000C90</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C90</idno><idno type="wicri:Area/PubMed/Checkpoint">000C90</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C90</idno><idno type="wicri:Area/Ncbi/Merge">000D77</idno><idno type="wicri:Area/Ncbi/Curation">000D77</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D77</idno><idno type="wicri:Area/Main/Merge">001B58</idno><idno type="wicri:Area/Main/Curation">001A50</idno><idno type="wicri:Area/Main/Exploration">001A50</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evidence-based initiation of dopaminergic therapy in Parkinson's disease.</title><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M" last="Miyasaki">Janis M. Miyasaki</name><affiliation wicri:level="1"><nlm:affiliation>The Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, ON, Canada. miyasaki@uhnresearch.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Movement Disorders Centre, Toronto Western Hospital, University Health Network, Toronto, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of neurology</title><idno type="eISSN">1432-1459</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (adverse effects)</term><term>Dyskinesia, Drug-Induced (prevention & control)</term><term>Evidence-Based Medicine (standards)</term><term>Humans</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Evidence-Based Medicine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M" last="Miyasaki">Janis M. Miyasaki</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21080195
|texte= Evidence-based initiation of dopaminergic therapy in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21080195" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |